Saturday, April 1, 2023
HomeMarketAmarin and ViewRay Stock See Action From Activist Investors

Amarin and ViewRay Stock See Action From Activist Investors

- Advertisement -

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Jan. 19 through Jan. 25, 2023. Source: VerityData

Activist Holdings


Sarissa Capital revealed a stake of 25,210,000 shares of the pharmaceutical company—6.2% of the outstanding stock. Sarissa Capital revealed on Jan. 10 that it had formally requested that Amarin call a special meeting of shareholders to nominate seven directors to Amarin’s board and to remove Per Wold-Olsen as chairman.

On Jan. 18, Sarissa provided its reasons for calling the special meeting, pointing to what it termed Amarin’s slow response to generic competition aimed at its cardiovascular-disease treatment Vascepa in 2022. Sarissa also cited Amarin’s missed goal of securing Vascepa reimbursement approvals in eight European markets, having obtained commitments for only five last year.


Hudson Executive Capital owns 15,752,093 shares of the maker of radiation-treatment equipment, or 8.7% of the outstanding stock. On Jan. 20, Hudson Executive and ViewRay signed a cooperative agreement that appoints Hudson Executive senior investment analyst Sai Nanduri as board observer until at least the start of 2024. In turn, Hudson Executive will abide by standstill provisions, including not owning more than a 14.9% interest in ViewRay, on its own or among a group.

Pitney Bowes

Hestia Capital Partners holds 12,575,000 shares of the mailing company, or 7.2% of the outstanding stock. That includes 125,000 shares bought on Dec. 22, 2022, and on Jan. 19, 2023, at prices ranging from $3.46 to $4.22. On Jan. 23, Hestia Capital revealed that it will nominate seven directors, including founder Kurt Wolf, at Pitney Bowes’ 2023 annual shareholders meeting. Hestia Capital is responding to what it argues is Pitney Bowes’ “misguided strategy, failed execution, and missed opportunities.”

Decreases In Holdings

Pediatrix Medical Group

Starboard Value slashed its holding in the pediatric-care-services firm to 3,348,578 shares. Without providing a reason, Starboard sold 2,566,422 Pediatrix shares from Dec. 9, 2022, through Jan. 20 at prices ranging from $15 to $16.17 apiece. Following the sales, Starboard now holds 4% of Pediatrix’s tradable stock, below the 5% threshold that would require disclosure of any future Pediatrix stock sales.

Expro Group Holdings

Oak Hill Advisors cut its position in the drilling-services company to 19,895,891 shares. That figure includes 198,154 underlying options. Oak Hill also holds another 44,770 Expro shares tied to restricted stock units. Oak Hill sold 9,200,000 Expro shares at the price of $16.50 each through a Jan. 12 secondary offering. Oak Hill now holds 18.3% of Expro’s outstanding stock. Senior partner Alan Schrager and partner Eitan Arbeter represent Oak Hill on Expro’s board.



- Advertisment -

Most Popular